武汉禾元生物科技股份有限公司 2025年年度业绩预告

Group 1 - The company forecasts a total profit loss of between -167 million to -143 million yuan for the year 2025, with a net profit attributable to the parent company also expected to be in the same range [3][4] - The expected net profit attributable to the parent company, after deducting non-recurring gains and losses, is projected to be between -191 million to -162 million yuan [4] - The anticipated operating revenue for 2025 is estimated to be between 45 million to 50 million yuan, representing a year-on-year increase of 78.46% to 98.29% [4] Group 2 - In the same period last year, the company reported a total profit loss of -151.37 million yuan and a net profit attributable to the parent company of -151.37 million yuan [6] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -166.75 million yuan [6] - The operating revenue for the previous year was 25.22 million yuan [8] Group 3 - The increase in sales revenue is attributed to the market introduction of the product "Aofumin" (recombinant human albumin injection) [9] - The production line for the related product is currently in a ramp-up phase, with capacity expected to gradually increase [9] - The company continues to maintain high levels of investment in research and development [10]